Federal health regulators have exercised new transaction review powers 15 times since acquiring authority in the aftermath of Steward Health Care's $9 billion bankruptcy collapse. The deals span hospital acquisitions, ambulatory surgery center roll-ups, and physician practice aggregations. None have been blocked. All took longer.

The authority stems from emergency rulemaking finalized in October, granting the Centers for Medicare & Medicaid Services expanded jurisdiction over change-of-ownership filings that previously received perfunctory approval. Steward's implosion—32 hospitals across eight states, $1.2 billion in unpaid medical supply invoices—created the political aperture. The Biden administration moved the rule through notice-and-comment in 47 days, citing patient safety and Medicare program integrity. The Trump administration has not rescinded it.

What changed is procedural violence dressed as administrative housekeeping. CMS now requires detailed financial disclosures from acquiring entities in transactions above $100 million or involving more than three facilities. The review window extends to 90 days from 30, with indefinite holds possible if regulators request supplemental materials. Operators report that CMS is asking for portfolio-wide leverage ratios, not just target-entity capitalization. One West Coast health system CFO described the new questionnaire as running 68 pages, compared to the previous 9-page standard form. The agency is building a deal database it did not previously maintain.

The 15 transactions reviewed to date include four hospital acquisitions by private equity-backed platforms, seven ambulatory surgery center consolidations, and four large physician group purchases. Median deal size sits near $240 million. The largest was a $580 million take-private of a regional health system by a growth equity fund operating through a management services organization structure. That file took 83 days to clear. Two others remain open past the standard window.

Allocators should recognize this as the opening phase of durable regulatory friction, not a temporary compliance burden. CMS is staffing a 12-person transaction review unit inside its Center for Clinical Standards and Quality,招聘 from DOJ Antitrust, state insurance departments, and restructuring advisory. The personnel buildout signals permanence. The agency has requested $18 million in additional funding for fiscal 2026 to expand the unit and retain outside financial advisors. Congress has been quiet.

The second-order effects will emerge in Q2 2025 as deal timelines stretch and financing certainty erodes. Private equity funds operating on 18-month deployment clocks face new calendar risk. Debt commitment letters typically expire after 90 days; the new CMS window aligns poorly with leveraged buyout mechanics. Operators are already building 45-day regulatory buffers into exclusivity periods and pushing for extended financing commitments. Bridge lenders are repricing accordingly. One credit fund attorney noted that healthcare LBO docs now include CMS approval as a financing condition precedent, which was unheard of in 2023.

Watch for three follow-on developments. First, whether CMS blocks a transaction outright—credible sources suggest the agency has twice requested voluntary restructurings to reduce post-deal leverage below 5.0x EBITDA, but has not formally denied an application. Second, whether Republican-led states challenge the rule's statutory basis; Texas and Florida have both signaled interest, though neither has filed. Third, and most material for capital deployment: whether the 90-day clock becomes 120 or 150 in practice as the unit scales. The average processing time for the last five cleared deals was 76 days. The trend is lengthening, not shortening.

Healthcare services multiples compressed 140 basis points in the last six months. Some of that is rate environment. Some is this.